Clinical Trial Info

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

Authored by
Staff

The primary objectives of this Phase 1 are:

To assess the occurrence of adverse events of special interest (AESIs) in participants treated with repeated subcutaneous (SC) doses of REGN10933+REGN10987 compared to placebo

To assess the concentrations of REGN10933 and REGN10987 in serum over time after single and repeated SC administration

The secondary objectives are:

To assess the safety and tolerability of repeated SC doses of REGN10933+REGN10987 compared to placebo

To assess attainment of target concentrations of REGN10933 and REGN10987 in serum after single and repeated SC administration

To assess the immunogenicity of REGN10933 and REGN10987